Shilpa Medicare Limited has informed the Exchange about Ex-parte ad-interim injunction order regarding pharmaceutical drug product

Litigation LossRegulatory & Legal View source PDF Explain this filing

SHILPAMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.0%Reaction day

₹318.60

prior close

₹317.90

announcement price

In-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.1%-1.0% vs market

Pharmaceuticals peers, median of 156sector-0.2%-0.8% vs sector

On the reaction day the stock moved 1.0 pts less than Nifty Microcap 250 and 0.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.7

10m

-0.7

15m

-0.9

30m

-0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.0-0.1-1.0-0.2-0.8

Next day

+0.9+1.3-0.4+0.5+0.4

-0.4+1.6-2.0+0.8-1.3

+0.6+2.5-1.9+1.8-1.2

-0.8+2.8-3.6+1.3-2.1

-0.0+2.1-2.1+1.6-1.7

-4.4+0.1-4.6+0.4-4.9

15d

-15.3-7.2-8.1-6.0-9.3

-8.5-4.4-4.1-5.6-2.9

+1.1-6.4+7.5-7.5+8.5

+9.1-15.1+24.2-17.1+26.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The Delhi High Court has issued an ex-parte ad-interim injunction on December 29, 2025, restraining Shilpa Medicare along with its material subsidiary Shilpa Pharma Lifesciences and wholly owned subsidiary FTF Pharma from manufacturing, selling, exporting, or supplying any pharmaceutical product containing Ruxolitinib or Ruxolitinib Salts API, citing alleged infringement of Patent No. IN269841 (a JAK Inhibitor compound). A court-appointed Local Commissioner also visited the company's premises to inspect records and stock registers; the company says it fully cooperated. Shilpa clarifies that the product in question was used only for research purposes and that there is no financial impact from this order. The company is evaluating legal options, including filing responses or appeals, and says normal business operations remain unaffected.

Likely market impact

Short-term impact appears limited as the company claims no financial exposure and operations are running as usual, but the patent dispute could become a longer-term overhang if the injunction is upheld or expanded. Retail investors should watch for updates on the company's legal response and any future revenue contribution from Ruxolitinib-related products.